ArticleCureus2024
Refractory Hypercalcemia of Malignancy in Squamous Cell Carcinoma of the Buccal Mucosa With Skeletal Muscle Metastasis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring a Rare Association: Systematic Review of Hypercalcemia in Nontuberculous Mycobacterial Infections.Microorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refractory hypercalcemia of malignancy (RHOM) is a challenging and often life-threatening condition characterized by persistently high serum calcium levels despite standard treatments. It is commonly associated with malignancies such as squamous cell carcinoma (SCC) of the lung, breast cancer, and multiple myeloma. However, studies on head and neck cancers, including SCC of the oral cavity, suggest that hypercalcemia can occur but is relatively rare. We report a case of a 45-year-old male with SCC of the buccal mucosa who presented with severe, refractory hypercalcemia. Despite aggressive hydration, bisphosphonates, calcitonin therapy, and glucocorticoids, serum calcium levels remained elevated. The patient was subsequently treated with hemodialysis, but despite this intervention, his clinical status did not improve, ultimately leading to his mortality. This case highlights the challenges in managing RHOM and underscores the need for better therapeutic strategies. Timely recognition and innovative treatment approaches are crucial for improving patient outcomes in refractory cases of hypercalcemia of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.